Response to: Allergy societies and the formula industry.

In 2020, the BSACI's policy on how it interacts with industry [1] was ratified at the annual general meeting by members. This policy enables BSACI to balance the advantages of working in partnership with industry to bring real benefit to patients while at the same time ensuring we do not compromise the integrity and independence of the BSACI. One of the drivers for this policy was the 2016 WHO guidance on the marketing of breastmilk substitutes (WHA resolution 69.9) [2].